secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001193125-25-130709
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha prices $187M stock offering; TSHA-102 achieves 100% milestone gain, FDA agrees on pivotal trial design
--------------------------------------------------------------------------------

- Issued 46.9M shares at $2.75/sh and 25.9M pre-funded warrants at $2.749; net proceeds ~$187.4M.
- Underwriters granted 30-day option for up to 10.9M additional shares; closing expected May 30.
- TSHA-102 in Rett syndrome: 100% (10/10) patients gained/regained ≥1 milestone post-treatment, with high dose outperforming low dose.
- FDA provided written alignment on single-arm pivotal Part B trial design; primary endpoint: developmental milestone gain/regain in patients ≥6 yrs.
- Astellas option to license TSHA-102 remains exercisable 90 days after receipt of Rett Data Package expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525130709/0001193125-25-130709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525130709/d948981d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-130709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer